News
Ihre Auswahl
forschen, produzieren, heilen, bilden / 18.09.2025
Talk in the Cube: IP STRATEGIES IN BIOTECHNOLOGY
We are excited to continue the Talks in the Cube with an expert discussion focused on Strategies for Intellectual Property Rights in Biotechnology.
Effective strategies for Intellectual Property (IP) in Biotechnology include using patents for new processes and products, applying trade secrets for complex bioengineering methods, and employing trademarks for branding. A comprehensive strategy also means building adequate patent portfolios through patent jungles or "Biobetters", monitoring and defending IP rights against infringement, and potentially using licensing agreements for technology transfer.
Our two esteemed experts who are trained natural scientists AND European Patent Attorneys. They will share their insights and experiences with us.
A Panel Discussion with
Dr. Sun Jin Lee, European Patent Attorney, European Patent Litigator (UPC), Maiwald GmbH, Munich
Dr. Oliver Ladendorf, LL.B., European Patent Attorney, Kraus & Lederer PartGmbH, Munich
Dr. Uwe Lohmeier, Berlin BioScience Academy (BBA), Campus Berlin Buch GmbH (Moderation).
Topics planned to be addressed
- Smart patenting for Biotech: Portfolios providing leverage and attracting investors
- Licensing of innovative technologies: Patents for organoids and CRISPR/Cas
- Biotech Patents and AI: Examples to influence innovations and to protect data-driven discoveries.
The talk will be followed by a networking event where you can socialize over snacks and drinks.
Target audience
Founders & scientists from start-ups, small and medium-sized life science companies and scientific institutions.
Costs
Participation is free of charge. Registration is requested.
When
Thursday, 18 September 2025
5:00 p.m. - 7:00 p.m.
Where
BerlinBioCube (Building D95), Campus Berlin-Buch, Robert-Rössle-Straße 10, 13125 Berlin
Quelle: BerlinBioscience Academy
Further information and registration
Alle News im Überblick
News Buch Berlin
Eine Chance für den Standort Berlin
Das Einstein Center for Early Disease Interception wird ab Januar 2026 mit sechs Millionen Euro gefördert. Im Interview erläutern Nikolaus Rajewsky und Leif Erik Sander aus dem Sprecherteam, warum neu...
weiter ...Ein Spin-off gegen neuromuskuläre Leiden
Ein Team um Mina Gouti hat aus humanen Stammzellen ein Modell erschaffen, an dem sich neue Wirkstoffe gegen neuromuskuläre Krankheiten erproben und bestehende Therapien verfeinern lassen.
weiter ...Entdecken, erfinden, ausgründen – wie Innovation in der Biomedizin gelingt
Interview mit der Leiterin der Abteilung Innovation & Entrepreneurship am Max Delbrück Center, Dr. Nevine Shalaby
weiter ...Termine Buch Berlin
20.03.2026, 08:45
Einladung: UniStem Day für Berliner Schülerinnen und Schüler aus Biokursen
Das German Stem Cell Network (GSCN) lädt die an Biologie interessierten Berliner Schülerinnen und Schüler (Biologie-Leistungskurse und Grundkurse) mit ihren Lehrkräften herzlich zum UniStem Day – zum ...
weitere Informationen22.09.2026, 09:00
/ Campus Berlin-Buch
GMP Biotech Summer School
Knowing and applying the Good Manufacturing Practice (GMP) regulations is one of the key elements in the manufacture of medicinal products for clinical trials and on an industrial level.
weitere Informationen